FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/01/100302 [Registered on: 05/01/2026] Trial Registered Prospectively
Last Modified On: 30/04/2026
Post Graduate Thesis  No 
Type of Trial  PMS 
Type of Study   Medical Device 
Study Design  Single Arm Study 
Public Title of Study   To evaluate the safety of Mirus Hemorrhoidal Circular Stapler among patients with hemorrhoids 
Scientific Title of Study   A prospective, single-arm, multicenter, real-world, post-market clinical follow-up study to evaluate the safety and performance of Mirus Hemorrhoidal Circular Stapler 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
MES/MIRUS HEMORRHOIDAL CIRCULAR STAPLER - 1 V1.0.0_01-Aug-25  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Kirankumar Shetty  
Designation  AGM - Product Performance & Engineering Department  
Affiliation  Meril Life Sciences Pvt. Ltd  
Address  Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad

Valsad
GUJARAT
396191
India 
Phone  9743700109  
Fax    
Email  kirankumar.shetty@merillife.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Kirankumar Shetty  
Designation  AGM - Product Performance & Engineering Department  
Affiliation  Meril Life Sciences Pvt. Ltd  
Address  Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad

Valsad
GUJARAT
396191
India 
Phone  9743700109  
Fax    
Email  kirankumar.shetty@merillife.com  
 
Details of Contact Person
Public Query
 
Name  Dr Kirankumar Shetty  
Designation  AGM - Product Performance & Engineering Department  
Affiliation  Meril Life Sciences Pvt. Ltd  
Address  Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad

Valsad
GUJARAT
396191
India 
Phone  9743700109  
Fax    
Email  kirankumar.shetty@merillife.com  
 
Source of Monetary or Material Support  
Meril Endosurgery Pvt.Ltd.MERIL PARK , E1-E3, SURVEY NO 135/2/B, 174/2, MUKTANAND MARG, CHALA, VAPI,VALSAD,GUJARAT,396191 
 
Primary Sponsor  
Name  Meril Life Sciences Pvt Ltd  
Address  Near Bilakhia Stadium, Survey no 135/139,Muktanand marg, Chala, Vapi-396191, Gujarat, India  
Type of Sponsor  Other [Medical Device Company] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 4  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Shashank Trivedi  GBH American Hospital  Department of General Surgery, Ground floor Meera Girls, 20-BHATT JI KI BARI, 101, Kothi Bagh, College Road, Kothi Bagh, Udaipur, Rajasthan 313004
Udaipur
RAJASTHAN 
9638338726

shashankjtrivedi@gmail.com 
Dr Sahdevsinh Chauhan  Hanumant Hospital  5th & 6th Floor, Anjaneya Icon, Kalubha Rd, opposite Surydeep Complex, Nanbhawadi, Panwadi, Bhavnagar, Gujarat 364001
Bhavnagar
GUJARAT 
9737506070

hanumanthospitals@gmail.com 
Dr Nilesh Dhariya  Initimate Clinic   Laproscopic Department,E-86, LIG Link Rd, near Lifeline Hospital, Shree Nagar Ext, Pushpa Nagar, Anurag Nagar, Indore, Madhya Pradesh 452011
Indore
MADHYA PRADESH 
7509355565

info@intimateclinic.in 
Dr Rakesh Shivhare  Pristyn Care Eminent Superspeciality Hospital  Pristyn Care, Eminent Hospital, Manorama Ganj, opp. Barwani Plaza Residential Road, Near Eureka Hospital, Old Palasia, Indore, Madhya Pradesh 452018
Indore
MADHYA PRADESH 
9826680273

drrakeshshivhare@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 4  
Name of Committee  Approval Status 
GBH Memorial Cancer Hospital Ethics Committee  Approved 
kiran Institutional Ethics Committee  Approved 
Rectitude Ethics Committee  Submittted/Under Review 
Rectitude Ethics Committee  Submittted/Under Review 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K649||Unspecified hemorrhoids,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NIl  NIL 
Comparator Agent  NIL  NIL 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  1.Participants aged 18 years or older, regardless of gender who undergo surgical treatment of hemorrhoidal disease throughout the anal canal using the Mirus™ Hemorrhoidal Circular Stapler.
2.Participants who are able to give voluntary, written informed consent to participate in this PMCF and from whom consent has been obtained. 
 
ExclusionCriteria 
Details  1.Participants who are unwilling or unable to sign the Informed Consent Document.
2.Participants with compressed tissue thickness less than 0.75 mm or greater than 1.5 mm.
3.Participants whose rectum internal diameter will not accommodate the instrument and accessories.
4.Participants with anal stenosis, severe mucosal edema, and severe fibrosis of hemorrhoidal tissue
5.Participants with necrotic or friable tissues and tissues having altered integrity.
6.Participants whose hemorrhoidal tissue has undergone multiple injections of hardening agents.
7.Participants currently undergoing anticoagulation therapy.
8.Participants with any anatomical or pathological condition that would compromise safe stapler placement or function.
9.Participants unable to achieve adequate tissue compression within the specified thickness parameters. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
1.Recurrence Rate
2. Stapled Hemorrhoidopexy Complications 
1. Time Frame: 3 months ± 7 days, 6 months ± 7 days, and 1 year ± 30 days.
2.Time Frame: Intra-operative, Discharge, 3 months ± 7 days, 6 months ± 7 days, 1 year ± 30 days 
 
Secondary Outcome  
Outcome  TimePoints 
1.Quality of Life
2.Pain
3.Operative Time
4. Length of Hospital Stay
5. Adverse events  
1. Time Frame: Baseline, 3 months ± 7 days, 6 months ± 7 days, and 1 year ± 30 days.
2.Time Frame: Baseline, Discharge, 3 months ± 7 days, 6 months ± 7 days, and 1 year ± 30 days
3.Time Frame: Intra-operative
4.Time Frame: Discharge
5.Time Frame: Discharge, 3 months ± 7 days, 6 months ± 7 days, and 1 year ± 30 days 
 
Target Sample Size   Total Sample Size="134"
Sample Size from India="134" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Post Marketing Surveillance 
Date of First Enrollment (India)   19/01/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
Study Name:A prospective, single-arm, multicenter, real-world, post- market clinical follow-up study to evaluate the safety and performance of Mirus Hemorrhoidal Circular Stapler.
Short Title:Mirus Hemorrhoidal Circular Stapler
Protocol ID, Version & Date:MES/MIRUS HEMORRHOIDAL CIRCULAR STAPLER -
1_Version 1.0.0_01-Aug-2025
Study Device:Mirus™ Hemorrhoidal Circular Stapler
Indication:Mirus™ Hemorrhoidal Circular Stapler has application throughout the anal canal to perform surgical treatment of hemorrhoidal disease.
Contraindication: Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids where the compressed tissue thickness is less than 0.75 mm or greater than 1.5 mm or where the rectum internal diameter will not accommodate the instrument and accessories. If the instrument is used on tissue less than 0.75 mm or greater than 1.5 mm thick, it may result in staple malformation or hemorrhage.
2. Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids when anal stenosis exists.
3.Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids when severe mucosal edema exists.
4. Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids when severe fibrosis of hemorrhoid tissue exists.
5. Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids when tissue has undergone multiple injections of a hardening agent at hemorrhoids.
6. Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids on the participants undergoing anti coagulation therapy.
7.Mirus™ Hemorrhoidal Circular Stapler should not be used to staple necrotic, friable tissues or have altered integrity, e.g., ischemic or edematous tissues.
Objective:The study aims to evaluate the safety and performance of Mirus™ Hemorrhoidal Circular Stapler.

Hemorrhoidal disease is one of the most common conditions identified in outpatient clinics, resulting in 3.3 million outpatient visits annually in the U.S., with a self-reported incidence of 10 million cases per year, affecting 4.4% of the population 
Currently, treatment options for hemorrhoidal disease (HD) range from conservative approaches, such as dietary changes and medications, to non-excisional methods like cryotherapy, sclerotherapy, laser photocoagulation, and rubber band ligation. For advanced cases, particularly grade III or IV hemorrhoids, or when conservative treatments fail in patients with persistent bleeding, surgical excision may be necessary .
Surgery is the most effective treatment for hemorrhoids and is particularly recommended for grade IV hemorrhoids (irreducible) and prolapsing hemorrhoids during defecation that may be manually reduced .
Traditional hemorrhoidal surgery, including Ferguson’s and Milligan-Morgan procedures, effectively removes hemorrhoids but causes significant postoperative pain due to external wounds. Stapled hemorrhoidopexy, introduced by Longo, has gained widespread acceptance for causing less pain and enabling faster recovery. This technique utilizes a specially designed circular stapling device that differs from traditional circular staplers used for creating full-thickness anastomoses .
Pain is the most common complication following hemorrhoidectomy procedures. Long-term complications include anal fissure, anal stenosis, incontinence, fistula, and hemorrhoidal recurrence. The significant pain associated with hemorrhoidectomies represents a major clinical concern .
The recently introduced laser hemorrhoidoplasty technique has been successfully applied to patients with hemorrhoids of all degrees. This method delivers laser energy into the interstitial tissue rather than the perianal vessels, resulting in tissue retraction and hemorrhoidal resolution. The technique produces less intense, shorter-duration pain and achieves satisfactory long-term outcomes. The distinctive feature of laser hemorrhoidoplasty is that the coagulated area remains invisible during the procedure since it lies beneath the healthy, uninjured mucosal layer.
 
Close